Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
OtherPerspective
Open Access

Antibody-drug conjugates in breast cancer: advances and prospects

Zhiqiang Shi, Yongjin Lu, Qiuchen Zhao, Yongsheng Wang and Pengfei Qiu
Cancer Biology & Medicine February 2025, 22 (2) 83-92; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0486
Zhiqiang Shi
1Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
2Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin 300202, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongjin Lu
1Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
3Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan 271016, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qiuchen Zhao
4Cancer Research UK Cambridge Centre PhD Programme, University of Cambridge, Cambridge CB2 0XZ, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongsheng Wang
1Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pengfei Qiu
1Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pengfei Qiu
  • For correspondence: qiu.pf{at}outlook.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 22 no. 2 83-92
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2024.0486
PubMed 
39960255

Published By 
Cancer Biology & Medicine
History 
  • Received November 1, 2024
  • Accepted January 17, 2025
  • Published online March 12, 2025.

Article Versions

  • previous version (February 17, 2025 - 04:46).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright: © 2025 The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Author Information

Funding

  • National Natural Science Foundation of China

    81672638

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 81672638).

Cited By...

  • 2 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 22 (2)
Cancer Biology & Medicine
Vol. 22, Issue 2
15 Feb 2025
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antibody-drug conjugates in breast cancer: advances and prospects
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Antibody-drug conjugates in breast cancer: advances and prospects
Zhiqiang Shi, Yongjin Lu, Qiuchen Zhao, Yongsheng Wang, Pengfei Qiu
Cancer Biology & Medicine Feb 2025, 22 (2) 83-92; DOI: 10.20892/j.issn.2095-3941.2024.0486

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Antibody-drug conjugates in breast cancer: advances and prospects
Zhiqiang Shi, Yongjin Lu, Qiuchen Zhao, Yongsheng Wang, Pengfei Qiu
Cancer Biology & Medicine Feb 2025, 22 (2) 83-92; DOI: 10.20892/j.issn.2095-3941.2024.0486
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Advances in ADC therapy
    • ADCs contribute to the precise classification of breast cancer
    • Biological mechanism underlying resistance to ADCs
    • ADC combination therapy
    • New ADCs
    • Summary
    • Conflict of interest statement
    • Author contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Protocol and statistical designs in classic clinical research—toripalimab series trial analysis
  • Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers
  • Beyond origin: multimodal AI synthesis to resolve cancers of unknown primary
Show more Perspective

Similar Articles

Subjects

  • Cancer immunology and immunotherapy
  • Breast cancer

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire